Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): February 1, 2006
GENEREX
BIOTECHNOLOGY CORPORATION
(Exact
Name of Registrant as Specified in Its Charter)
|
Delaware
|
000-25169
|
98-0178636
|
|
(State
or Other Jurisdiction of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
| |
|
|
33
Harbour Square, Suite 202, Toronto, Ontario Canada M5J
2G2
(Address
of Principal Executive Offices) (Zip
Code)
Registrant’s
telephone number, including area code: (416)
364-2551
N/A
(Former
name or former address, if changed since last report.)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
rWritten
communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
rSoliciting
material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
rPre-commencement
communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
rPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
4.01 Changes
In Registrant’s Certifying Accountant.
On
February 1, 2006, Generex Biotechnology Corporation engaged Danziger &
Hochman, Chartered Accountants (“Danziger”) to serve as the independent public
accountants to audit our financial statements for the fiscal year ending July
31, 2006.
During
our fiscal years ended July 31, 2004 and July 31, 2005, and the interim periods
through February 1, 2006, we have had no consultations with Danziger concerning:
(a) the application of accounting principles to a specific transaction or the
type of opinion that might be rendered on our financial statements as to which
we received oral advice that was an important factor in reaching a decision
on
any accounting, auditing or financial reporting issue; or (b) any disagreements,
as defined in Item 304(a)(1)(iv) of Regulation S-K.
The
appointment of Danziger as independent public accountants was unanimously
approved by the Audit Committee of our Board of Directors.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
GENEREX
BIOTECHNOLOGY CORPORATION |
|
|
|
| Dated:
February 2, 2006 |
By: |
s/
Rose C.
Perri
|
| |
Chief Operating Officer and Chief Financial
Officer
(principal financial officer) |
| |
|